Shield insists merger deal with Axis is underway
This article was originally published in Clinica
Shield Diagnostics maintains that the deal to merge with homocysteine test rival Axis Biochemicals is still on, despite persistent rumours in the UK national press that adverse reaction from the Norwegian company's major shareholders may yet scupper the deal.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.